MYB 抗体 (AA 119-135)
Quick Overview for MYB 抗体 (AA 119-135) (ABIN6940143)
抗原
See all MYB 抗体适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
抗原表位
- AA 119-135
-
纯化方法
- Purified by Protein A/G
-
免疫原
- A synthetic peptide, corresponding to aa 119-135 (RRKVEQEGYPQESSKAG) of c-myb onco protein, coupled to KLH
-
亚型
- IgG1 kappa
-
-
-
-
应用备注
-
Positive Control: Jurkat, MOLT-4, COLO or BT-20 cells. Colon or breast carcinomas.
Known Application: ELISA (Use Ab at 2-4 μg/mL for coating) (Order Ab without BSA), Optimal dilution for a specific application should be determined.
-
限制
- 仅限研究用
-
-
-
浓度
- 200 μg/mL
-
缓冲液
- 10 mM PBS with 0.05 % BSA & 0.05 % azide.
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C,-80 °C
-
储存方法
- Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.
-
有效期
- 24 months
-
-
- MYB (V-Myb Myeloblastosis Viral Oncogene Homolog (Avian) (MYB))
-
别名
- MYB
-
背景
- The highly leukemogenic avian retrovirus E26 contains two oncogenes, v-Myb and v-Ets, which are expressed together as a fusion protein. The cellular homolog of v-Myb, designated c-Myb, encodes a transcription factor. Deletion or disruption of a negative regulatory domain mapping within the carboxy-terminal domain of c-Myb results in enhanced transactivating capacity and in parallel, leads to activation of its ability to transform hemopoietic cells. c-Myb is expressed preferentially, but not exclusively, in immature hemopoietic cells and its expression decreases as cells differentiate.
-
分子量
- ~75kDa
-
基因ID
- 4602
-
UniProt
- P01104
-
途径
- Chromatin Binding, Positive Regulation of Immune Effector Process
抗原
-